Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
BORTEZOMIB JN, BORTEZOMIB JUNO (Juno Pharmaceuticals Pty Ltd)
Product name
BORTEZOMIB JN, BORTEZOMIB JUNO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
240 working days (255)
Active ingredients
bortezomib
Registration type
New generic medicine
Indication
BORTEZOMIB JUNO, BORTEZOMIB JN (powder for injection) in combination with melphalan and prednisone are indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.
Bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.
Bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.